Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union
Abstract Background Sodium oxybate (Xyrem®), approved by the European Medicines Agency (EMA) for narcolepsy with cataplexy, is only available through risk mitigation programs due to potential adverse effects including respiratory and central nervous system depression, neuropsychiatric events, and mi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2020-09-01
|
| Series: | Drugs - Real World Outcomes |
| Online Access: | https://doi.org/10.1007/s40801-020-00212-9 |